Outcomes based on age in the phase 3 Meteor trial of cabozantinib (cabo) vs everolimus (eve) in patients with advanced renal cell carcinoma (RCC)

被引：0
|
作者：
Bergmann, L. [1 ]
Donskov, F. [2 ]
Motzer, R. J. [3 ]
Voog, E. [4 ]
Hovey, E. J. [5 ]
Gruellich, C. [6 ]
Nott, L. M. [7 ]
Cuff, K. E. [8 ]
Gil, T. [9 ]
Jensen, N., V [10 ]
Chevreau, C. [11 ]
Negrier, S. [12 ]
Depenbusch, R. [13 ]
Cornelio, I [14 ]
Champsaur, A. [14 ]
Escudier, B. J. [15 ]
Pal, S. K. [16 ]
Powles, T. [17 ]
Choueiri, T. K. [18 ]
机构：
[1] Univ Klin Frankfurt Hosp, Frankfurt, Germany
[2] Aarhus Univ Hosp, Aarhus, Netherlands
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Ctr Jean Bernard Clin Victor Hugo, Le Mans, France
[5] Prince Wales Hosp, Sydney, NSW, Australia
[6] Natl Ctr Tumor Dis NCT Heidelberg, Heidelberg, Germany
[7] Royal Hobart Hosp, Hobart, Tas, Australia
[8] Princess Alexandra Hosp, Woolloongabba, Australia
[9] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium
[10] Odense Univ Hosp, Odense, Denmark
[11] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[12] Ctr Leon Berard, Ctr Reg Lutte Canc, Lyon, France
[13] Onkodok GmbH Dedicated Res Facil, Gutersloh, Germany
[14] Exelixis Inc, San Francisco, CA USA
[15] Gustave Roussy Canc Ctr, Villejuif, France
[16] City Hope Comprehens Canc Ctr, Duarte, CA USA
[17] Queen Mary Univ London, Barts Canc Inst, London, England
[18] Dana Farber Canc Ctr, Boston, MA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P600
引用
收藏
页码：200 / 201
页数：2
相关论文
共 50 条
  • [31] Effect of prior systemic therapy on clinical outcomes with cabozantinib vs everolimus in advanced renal cell carcinoma: Results from the phase 3 METEOR study
    Grande, E.
    Choueiri, T. K.
    Motzer, R. J.
    Escudier, B.
    Pal, S.
    Kollmannsberger, C.
    Pikiel, J.
    Gurney, H.
    Rha, S. Y.
    Park, S. H.
    Geertsen, P. F.
    Goupil, M. Gross
    Suarez, C.
    Arroyo, A.
    Dean, M.
    George, D.
    Powles, T.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S197 - S198
  • [32] Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial
    Cella, David
    Escudier, Bernard
    Tannir, Nizar M.
    Powles, Thomas
    Donskov, Frede
    Peltola, Katriina
    Schmidinger, Manuela
    Heng, Daniel Y. C.
    Mainwaring, Paul N.
    Hammers, Hans J.
    Lee, Jae Lyun
    Roth, Bruce J.
    Marteau, Florence
    Williams, Paul
    Baer, John
    Mangeshkar, Milan
    Scheffold, Christian
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (08) : 757 - +
  • [33] Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
    Denize, Thomas
    Farah, Subrina
    Cimadamore, Alessia
    Flaifel, Abdallah
    Walton, Emily
    Sticco-Ivins, Maura A.
    Labaki, Chris
    Braun, David A.
    Sun, Maxine
    Wang, Evelyn
    Xie, Wanling
    Choueiri, Toni K.
    Signoretti, Sabina
    CLINICAL CANCER RESEARCH, 2022, 28 (04) : 748 - 755
  • [34] Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
    Choueiri, Toni K.
    Escudier, Bernard
    Powles, Thomas
    Tannir, Nizar M.
    Mainwaring, Paul N.
    Rini, Brian I.
    Hammers, Hans J.
    Donskov, Frede
    Roth, Bruce J.
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Agarwal, Neeraj
    Sternberg, Cora N.
    McDermott, David F.
    Aftab, Dana T.
    Hessel, Colin
    Old, Christian Scheff
    Schwab, Gisela
    Hutson, Thomas E.
    Pal, Sumanta
    Motzer, Robert J.
    LANCET ONCOLOGY, 2016, 17 (07): : 917 - 927
  • [35] Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
    Schmidinger, Manuela
    Motzer, Robert J.
    Rolland, Frederic
    Straehler, Michael
    Rink, Michael
    Retz, Margitta
    Csoszi, Tibor
    McCaffrey, John A.
    De Giorgi, Ugo
    Caserta, Claudia
    Duran, Ignacio
    Benzaghou, Fawzi
    Clary, Douglas O.
    Albiges, Laurence
    Choueiri, Toni K.
    Tannir, Nizar M.
    ACTA ONCOLOGICA, 2022, 61 (01) : 52 - 57
  • [36] A phase 3 randomized study of cabozantinib (XL184) vs everolimus in subjects with clear cell renal cell carcinoma (METEOR)
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Cella, D.
    Lee, Y.
    Laird, D. A.
    Scheffold, C.
    Motzer, R. J.
    BJU INTERNATIONAL, 2013, 112 : 4 - 4
  • [37] Phase 2 trial for sequential treatment of high dose cabozantinib (CABO) or CABO plus nivolumab (NIVO) on/after progression on CABO monotherapy in advanced renal cell carcinoma (RCC): Seq-Cabo
    Qin, Qian
    Brugarolas, James
    Hammers, Hans J.
    Arafat, Waddah
    Courtney, Kevin Dale
    Wang, Jue
    Jiang, Changchuan
    Zhang, Song
    Cowey, Charles Lance
    Hutson, Thomas E.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Expression of the receptor tyrosine kinase AXL and clinical outcomes to cabozantinib and everolimus in patients with metastatic renal cell carcinoma enrolled in the METEOR trial
    Laimon, Yasmin Nabil
    Paul, Morgan
    Ghandour, Fatme
    El Ahmar, Nourhan
    Matar, Sayed
    Denize, Thomas
    Sheshdeh, Aseman Bagheri
    Savla, Varunika
    Mohanna, Razan Assaad
    Sun, Maxine
    Saliby, Renee Maria
    Saad, Eddy
    Machaalani, Marc
    Braun, David A.
    Aftab, Dana T.
    Xie, Wanling
    Choueiri, Toni K.
    Signoretti, Sabina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).
    Motzer, Robert J.
    Sharma, Padmanee
    McDermott, David F.
    George, Saby
    Hammers, Hans J.
    Srinivas, Sandhya
    Tykodi, Scott S.
    Sosman, Jeffrey Alan
    Procopio, Giuseppe
    Plimack, Elizabeth R.
    Castellano, Daniel E.
    Gurney, Howard
    Donskov, Frede
    Bono, Petri
    Wagstaff, John
    Gauler, Thomas Christoph
    Ueda, Takeshi
    Zhao, Huanyu
    Waxman, Ian M.
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [40] Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma
    Hainsworth, John D.
    Spigel, David R.
    Burris, Howard A., III
    Waterhouse, David
    Clark, Bobby L.
    Whorf, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2131 - 2136
12345